SLC5A2 and diabetic kidney disease: Few effective drugs had been existed to hinder DKD progression, however, sodium-glucose cotransporter 2 inhibitor (SGLT2i) has recently been expected to suppress DKD progression (Wanner et al., 2016; Neal et al., 2017; Wiviott et al., 2019).